...treat atopic dermatitis. Rinvoq is approved in the U.S. and Europe to treat rheumatoid arthritis. TG’s ublituximab...
...trialsTG Therapeutics Inc. (NASDAQ:TGTX) said the Phase III ULTIMATE I and ULTIMATE II studies of ublituximab...

...endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab...
...growth factor VEGF-A - Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...

...He anticipates TG-1801 will have single-agent activity, but sees opportunities to combine the compound with ublituximab...

...data 2H19 LFB S.A. / TG Therapeutics Inc. (NASDAQ:TGTX) / Ildong Pharmaceutical Co. Ltd. (KRX:000230) Ublituximab...

...on Sept. 25 after the company said it will not seek accelerated approval of ublituximab (TG-1101...
...Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Ublituximab (TG-1101...
...Phase III ongoing Milestone: Phase III data (2019); submit regulatory application (2019) Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...

...$5.15 on Tuesday after the company said it will not seek accelerated approval of ublituximab (TG-1101...
...more information about duration of response and safety. TG said UNITY-CLL's efficacy data remain blinded. Ublituximab...
...OTCQX:RHHBY) plus chlorambucil in both treatment-naïve and relapsed or refractory CLL patients. Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...

...date 9/16/18 TG Therapeutics Inc. (NASDAQ:TGTX) / Rhizen Pharmaceuticals S.A. Umbralisib (TGR-1202) and ublituximab (TG-1101, TGTX-1101...

...3-kinase (PI3K) delta inhibitors. Top-line data from the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101...
...PI3K delta inhibitor, and ublituximab is a glycoengineered mAb against CD20. TG has rights to ublituximab...

...sclerosis. Ublituximab is a glycoengineered mAb against CD20. Among 38 evaluable patients with relapsing MS, ublituximab...
...Patients received placebo or three infusions of IV ublituximab in one of five dose cohorts. Ublituximab...
...LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Ublituximab (TG-1101, TGTX-1101...

...sclerosis. Ublituximab is a glycoengineered mAb against CD20. Among 38 evaluable patients with relapsing MS, ublituximab...
...baseline (p=0.0005). Among 40 evaluable patients, 97.5% of patients were relapse free at week 24. Ublituximab...
...Patients received placebo or three infusions of IV ublituximab in one of five dose cohorts. Ublituximab...